Clinical Validation Guided by Scientific Rigor
FAST>ER™ is being evaluated through a structured clinical validation program designed to generate objective evidence aligned with regulatory and clinical expectations.
Validation efforts focus on assessing biomarker performance, clinical relevance, and integration within real-world care environments.
Clinical validation is conducted to support appropriate regulatory pathways and intended use definitions.
Study Design Principles
Validation studies are designed to reflect real-world clinical settings and workflows.
Core design considerations include:
- Prospective sample collection where feasible
- Clearly defined inclusion and exclusion criteria
- Use of accepted clinical and laboratory reference methods
- Blinded analysis to reduce bias
Study protocols are developed with input from clinical collaborators and scientific advisors.
Validation Philosophy
Clinical validation is guided by established principles used in diagnostic development:
- Alignment with intended use
- Comparison to appropriate reference standards
- Evaluation in relevant patient populations
- Transparency and reproducibility of methods
The objective is to generate high-quality evidence that supports clinical interpretation and regulatory review.
Reference Standards
FAST>ER™ performance is evaluated in comparison to established reference standards appropriate to the clinical context.
Depending on the study design, reference methods may include:
- Laboratory-based analytical techniques
- Standard clinical imaging modalities
- Clinical assessment frameworks
Reference standards are selected to ensure relevance, rigor, and interpretability.
Data Analysis & Interpretation
Clinical data are analyzed using predefined statistical and analytical approaches appropriate to study objectives.
Interpretation emphasizes:
- Understanding biomarker behavior within clinical context
- Assessing consistency across sub-populations
- Identifying limitations and confounding factors
Analytical tools may support interpretation, but clinical judgment remains central.
From Validation to Clinical Use
Clinical validation represents a critical step in translating biomarker technology into responsible clinical use.
Findings from validation studies inform:
- Refinement of intended use
- Labeling and instructions for use
- Post-market evaluation strategies
Deployment decisions are guided by evidence, regulatory clearance, and clinical readiness.
Regulatory Alignment
Clinical validation activities are designed to align with applicable regulatory frameworks, including those governing in vitro diagnostics.
Considerations include:
- Intended use definition
- Risk classification
- Evidence requirements by jurisdiction
Validation data are generated to support regulatory submissions as appropriate.